Valuation: Clarity Pharmaceuticals Ltd

Market Cap 866M 604M 528M 487M 449M 847M 58.2B 5.83B 2.29B 28.51B 2.27B 2.22B 98.13B P/E 2026 *
-7.88x
P/E 2027 * -7.25x
Enterprise Value 705M 492M 430M 397M 366M 689M 47.38B 4.74B 1.87B 23.2B 1.85B 1.81B 79.88B EV / Sales 2026 *
-
EV / Sales 2027 * 874x
Free-Float
79.07%
Yield 2026 *
-
Yield 2027 * -
1 day-5.31%
1 week-3.73%
Current month+8.41%
1 month+5.94%
3 months-25.88%
6 months-30.12%
Current year-31.36%
1 week 2.31
Extreme 2.31
2.53
1 month 1.8
Extreme 1.8
2.65
Current year 1.8
Extreme 1.8
4.26
1 year 1.8
Extreme 1.8
5.87
3 years 0.86
Extreme 0.865
8.98
5 years 0.36
Extreme 0.36
8.98
10 years 0.36
Extreme 0.36
8.98
Manager TitleAgeSince
Chief Executive Officer - 11/10/2024
Chief Executive Officer - 01/01/2010
Director of Finance/CFO - 04/04/2022
Director TitleAgeSince
Chairman - 01/11/2013
Director/Board Member - 01/10/2010
Director/Board Member 72 29/03/2016
Date Insider Type Main position Quantity % Market Cap.
4/22/26 A Sell

Chief Executive Officer

360,896 0.0969%
11/28/25 A Free

Chief Operating Officer

287,530 0.0773%
11/28/25 A Free

Chief Operating Officer

199,909 0.0537%
Change 5-day change 1-year change 3-year change Capi.($)
-5.31%-3.73%-40.36%+168.21% 604M
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -3.03%-2.73%+32.45%+182.46% 23.42B
Weighted average by Cap. -2.81%-2.36%+39.34%+143.19%

Financials

2026 *2027 *
Net sales - 933K 652K 570K 526K 484K 913K 62.76M 6.28M 2.47M 30.74M 2.45M 2.39M 106M
Net income -108M -75.3M -65.81M -60.73M -55.97M -106M -7.25B -726M -285M -3.55B -283M -277M -12.23B -121M -84.42M -73.78M -68.08M -62.75M -118M -8.13B -814M -320M -3.98B -317M -310M -13.71B
Net Debt -161M -112M -98.23M -90.64M -83.55M -157M -10.82B -1.08B -426M -5.3B -422M -413M -18.25B -49.52M -34.58M -30.22M -27.88M -25.7M -48.44M -3.33B -333M -131M -1.63B -130M -127M -5.61B
Logo Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing targeted copper theranostics based on its SAR Technology Platform. It is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.
Employees
88
Date Price Change Volume
17/07/26 A$2.320 -5.31% 2,561,920
16/07/26 A$2.450 0.00% 2,230,007
15/07/26 A$2.450 +2.08% 2,681,731
14/07/26 A$2.400 -0.83% 6,127,258
13/07/26 A$2.420 +0.41% 1,371,003
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.320AUD
Average target price
7.128AUD
Spread / Average Target
+207.22%

Annual profits - Rate of surprise